Quest Diagnostics Inc vs Live Nation Entertainment, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.78 (market cap $25.48B), while Live Nation Entertainment, Inc. trades at $172.04 (market cap $39.92B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Live Nation Entertainment, Inc. for 72 Days on average.
| DGX | LYV | |
|---|---|---|
Market Cap | $25.48B | $39.92B |
Volume | 941,866 | 1,982,609 |
Sector | Health | Media |
52-Week High | $247.45 | $188.46 |
52-Week Low | $173.49 | $125.61 |
Typical Hold Time | 56 Days | 72 Days |
Enterprise Value | $31.23B | $42.13B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
LYV trades at $172.10, up 0.74% today, with a bullish technical signal and strong analyst support. Revenue grew to $25.20B in 2025, though net income margin narrowed to 1.96%. Recent news highlights robust fan demand and strategic partnerships, while the stock faces high valuation multiples and regulatory scrutiny.
Outlook remains positive with a consensus price target of $208.18, but risks include elevated P/E of 117.49, debt levels, and legal uncertainties. Earnings momentum is mixed, with Q2 2026 beating estimates but Q1 and Q4 2025 missing, underscoring execution challenges amid growth.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →